A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

Sanofi has been given a reprimand by the UK's Prescription Medicines Code of Practice Authority (PMCPA), after admitting that ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

Giusy Di Conza, head of research at small molecule cancer therapeutics firm iOnctura, said ADCs were “heralding a shift ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...